Evidence map›Paper›PMID 42356127›Full record

ArticleMedicina (Kaunas, Lithuania)2026

Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

Mehmet Mutlu Kidi, Hatice Asoglu, Metehan Soysal, Tolga Koseci, Ismail Oguz Kara, Berksoy Sahin, Semra Paydas, Musa Barış Aykan, Nuri Karadurmus, Ibrahim Barista and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mehmet Mutlu KidiDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Türkiye.ORCID 0000-0002-4750-720X
Hatice AsogluDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Türkiye.ORCID 0009-0000-1366-5552
Metehan SoysalDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Türkiye.ORCID 0009-0008-8606-5601
Tolga KoseciDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Türkiye.
Ismail Oguz KaraDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Türkiye.
Berksoy SahinDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Türkiye.
Semra PaydasDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Türkiye.ORCID 0000-0003-4642-3693
Musa Barış AykanDepartment of Medical Oncology, Gülhane Training and Research Hospital, Ankara 06010, Türkiye.ORCID 0000-0001-7538-9119
Nuri KaradurmusDepartment of Medical Oncology, Gülhane Training and Research Hospital, Ankara 06010, Türkiye.
Ibrahim BaristaDepartment of Medical Oncology, Hacettepe University, Ankara 06230, Türkiye.ORCID 0000-0002-5733-439X
Serkan AkinDepartment of Medical Oncology, Hacettepe University, Ankara 06230, Türkiye.
Fatih KusDepartment of Medical Oncology, Hacettepe University, Ankara 06230, Türkiye.ORCID 0000-0003-1650-154X
Meltem Olga AkayDepartment of Hematology, Koc University Hospital, Istanbul 34010, Türkiye.
Hakan KalyonDepartment of Hematology, Koc University Hospital, Istanbul 34010, Türkiye.
Can BogaDepartment of Hematology, Baskent University Adana Dr. Turgut Noyan Hospital, Adana 01250, Türkiye.
Hakan OzdoguDepartment of Hematology, Baskent University Adana Dr. Turgut Noyan Hospital, Adana 01250, Türkiye.
Ertugrul BayramDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01250, Türkiye.ORCID 0000-0001-8713-7613

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, B-CellLymphoma, Large B-Cell, DiffuseAdultAgedCohort StudiesCyclophosphamideDoxorubicinEtoposideFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrednisonePrognosisCyclophosphamideDoxorubicinEtoposidePrednisoneVincristinediffuse large B-cell lymphomadose-adjusted EPOCH-Rdouble-expressor lymphomadouble-hit lymphomamolecular prognosisprimary mediastinal B-cell lymphomareal-world evidence

Identifiers

PMID42356127
PMCPMC13304182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.